{"id":"W4410463538","doi":"10.1016/j.esmoop.2025.104671","title":"117P PIK3CA mutational status concordance between plasma and tumor in HER2+ advanced breast cancer (ABC) patients (pts) of ALPHABET (GEICAM/2017-01_IBCSG 62-20_BIG 18-04) trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Ipsen; Universitat de València; PharmaMar; Astellas Pharma; Seagen; Sociedad Española de Oncología Médica; BeiGene; Mersana Therapeutics; AstraZeneca España; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Dana-Farber Cancer Institute; McGill University; Merck KGaA; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer","keywords":"Concordance; Breast cancer; Oncology; Internal medicine; Medicine; Alphabet; Cancer; HER2 negative; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005539092,0.0001018471,0.0003701032,0.0002263621,0.0001380554,0.0006431849,0.0001428944,0.0001950551,0.002692288],"category_scores_gemma":[0.00151644,0.00009926759,0.0001257918,0.0003378452,0.0001349686,0.0002041798,0.0002358132,0.0003469591,0.0004093676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002960762,"about_ca_system_score_gemma":0.0002130303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005975657,"about_ca_topic_score_gemma":0.001131888,"domain_scores_codex":[0.9996892,0.0001149323,0.0000272455,0.00006806711,0.00006603773,0.00003448006],"domain_scores_gemma":[0.9994614,0.0001856699,0.0001526126,0.00005223562,0.00006155,0.00008649252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07912739,0.0005984677,0.7763883,0.000297656,0.000456095,0.0004716138,0.0002422344,0.0007249354,0.03869749,0.0003270389,0.003702724,0.09896602],"study_design_scores_gemma":[0.003029702,0.01065496,0.9656075,0.00003638148,0.0004747609,0.001747236,0.0001641221,0.00143872,0.01011209,0.0003609459,0.006357608,0.00001592265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965988,0.0004652929,0.0001097237,0.00007430896,0.0000131285,0.00003342331,0.0008067334,0.00001261759,0.001886053],"genre_scores_gemma":[0.9976594,0.0001285091,0.0002502486,0.00006596138,0.00002479749,0.00002669494,0.001298845,0.00000854985,0.0005368051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002692288,"threshold_uncertainty_score":0.00900656,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02253178367579364,"score_gpt":0.3512807230497896,"score_spread":0.328748939373996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}